Tender detail
Supply of selective immunosuppressants containing ravulizumab
Summary
The Institute for Clinical and Experimental Medicine is procuring parenteral medicines containing ravulizumab (ATC L04AJ02) for patients with approved indications. The procurement consists of one lot, with an estimated value of CZK 352,260,000 and a planned duration of 48 months. The medicines will be supplied for use at the Institute in Prague.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.